

# eicnhl scientific meeting

28<sup>th</sup> and 29<sup>th</sup> November, IDIBAPS-HOSPITAL CLINIC

Centre Esther Koplowitz (CEK), Calle del Rosselló, 149, 08036 Barcelona

	Scientific session
	Special session
	Joint session
	Coffee break /Lunch
	Amusement time

\* Remote connection

## Day 1 – Thursday, 28<sup>th</sup> November

8:30-9:00	Registration
9:00-9:15	Welcome Dr. Elias Campo (IDIBAPS Director)/AECC representative TO BE CONFIRMED
<b>Session 1. eicnhl business meeting. Chairs: eicnhl Board Cooperation with other societies, webpage, young NHL, etc</b> <i>09:15-10:30 Auditorium Esteve, CEK</i>	
<b>Session 2. Transversal international projects. Chair: Andishe Attarbaschi</b> <i>10:30-11:00 Auditorium Esteve, CEK</i>	
10:30-10:45	Kick-off" of the international rare NHL registry (IRNHRLR). Andishe Attarbaschi (St. Anna Kinderspital, BFM-Group-AU)
10:45-11:00	Update on the eicnhl R/R Registry and current SIOPE-European Standard Clinical Practice (ESCP) Project. Jaime Verdú (H. Clinic-INCLIVA, SEHOP-Group, ESP)
<b>11:00-11:30 COFFEE BREAK</b>	
<b>Session 3. Parallel sessions. 11:30-13:30</b> <b>a) Pathology Session: B-NHL in the context of Inborn Errors of Immunity (IEI). Room Margarita Salas, CEK</b> <b>b) LBL session. Chairs: Jan Loeffen, Lara Mussolin. Auditorium Esteve, CEK.</b>	
11:30-11:40	Update on the status of the trial LBL 2018 & HEM-iSMART. Stephanie Mueller (UKM, BFM Group-GER)
11:40-11:50	Validation study of retrospective molecular aberrations in BCP-LBL in the LBL2018 cohort. Jan Loeffen (PMC, NL)
11:50-12:00	Case Report I: Case report of a patient with T-LBL and histiocytic sarcoma. Jan Loeffen (PMC, NL)
12:00-12:10	Case Report II: The history of two patients with early relapse of lymphoblastic lymphoma. Grazyna Wrobel (UM Wroklaw, POL)
12:10-12:20	T-ALL, T-LBL and clonal evolution. Gerrit Randau/Marcel te Vrugt/Birgit Burkhardt (UKM, BFM Group-GER)
12:20-13:30	Recent results and next steps of the translational research and international collaboration on T-LBL cases with NOTCH1 fusions:
	<ul style="list-style-type: none"> <li>• Optimizing diagnostics in Notch1 fused T-LBL patients: molecular studies as well as blood biomarker CCL17. Roland Kuiper (PMC, NL) 15 min</li> <li>• NOTCH1 FISH set-up experience. Julia Salmerón (IDIBAPS-SEHOP-Group, ESP) 5 min</li> <li>• Status of the international activities and next steps. Gerrit Randau &amp; Marcel te Vrugt (UKE, UKM, BFM Group-GER); Jan Loeffen (PMC, NL) 50 min</li> </ul>

<b>13:30-14:30 LUNCH</b>	
<b>Session 4. Parallel sessions. 14:30-15:30</b>	
<b>a) Pathology Session: B-NHL in IEI / ALK-negative ALCL. Room Margarita Salas, CEK</b>	
<b>b) B-NHL session. Chairs: Veronique Minard, Alan Chiang. Auditorium Esteve, CEK.</b>	
14:30-14:40	Update on B-NHL 2013 and status of B-NHL 2025, iMatrix-Glo and M20-429 (Epcoritamab). Amelie Alfert, Birgit Burkhardt (UKM, BFM Group-GER)
14:40-14:50	INTER-B-NHL 2025. Véronique Minard-Colin (Gustave Roussy, FR)
14:50-15:00	Next upfront PMLBL eicnhl trial. Friederike Meyer – Wentrup (PMC, NL)
15:00-15:10	Update on GLOBNHL and other trials in R/R B NHL: Amos Burke * (CRUK Cambridge, UK), Veronique Minard (Gustave Roussy, FR)
15:10-15:20	scRNAseq in Burkitt lymphoma. Lara Mussolin (IRP Padova, AIEOP, IT)
15:20-15:30	High-grade B-cell lymphoma with 11q aberrations – a joint eicnhl-i-BFM project. Andishe Attarbaschi (St. Anna Kinderspital, BFM-Group AU)
15:30-15:40	Deciphering the molecular mechanisms behind IRF4 rearranged large B-cell lymphomas. A Colmenero (IDIBAPS-SEHOP Group, ESP)
<b>15:40-16:00 COFFEE BREAK</b>	
<b>SPECIAL SESSION</b>	
16:00-16:30 Auditorium Esteve, CEK	
<b>Topic: Clinico-biological perspectives in large B-cell lymphoma in adults</b>	
<b>Dr. Armando Lopez-Guillermo. Senior Consultant Hematology Department, Hospital Clinic Barcelona.</b>	
<b>Session 5. Parallel sessions (Continuation). 16:30-16:50</b>	
16:30-16:40	Lymphomas in IEI: the French experience and future eicnhl collaborations. Veronique Minard (Gustave Roussy, FR)
16:40-16:50	Unravelling the genetic basis of pediatric B-cell Non-Hodgkin lymphoma pathogenesis in patients with underlying inborn errors of immunity. S Mato (IDIBAPS-SEHOP Group, ESP)
<b>JOINT SESSION: Pathologists – Physicians - Researchers</b>	
16:50-17:20 Auditorium Esteve, CEK	
<b>Topic: Challenges in IEI B-NHL diagnosis: summary of reviewed cases</b>	
<b>Dr. O. Balagué (H. Clinic-SEHOP Group, ESP)</b>	
18:00	Cultural walk and Young eicnhl after-work
20:30	Tapas Barcelona Restaurant LA BARRA <a href="https://www.la-barra.com/">C/ Comte d'Urgell, 240, L'Eixample, 08036 Barcelona</a>

**Day 2 – Friday, 29<sup>th</sup> November (\***

*Remote connection)*

<b>Session 1. Parallel sessions. 08:00-09:30</b> <b>a) Pathology Session: ALK-negative ALCL. Room Margarita Salas, CEK</b> <b>b) ALCL session. Chairs: Willi Woessmann, Lara Mussolin. Auditorium Esteve, CEK.</b>	
08:00-08:05	Update on ALCL-VBL Study. Willi Woessmann (UKE-BFM Group-GER)
08:05-08:15	Update on BrigaPED Study and NIVO-ALCL Study. Charlotte Rigaud (Gustave Roussy, FR)*
08:15-08:25	Update on NIVO-ALCL Study. Charlotte Rigaud (Gustave Roussy, FR)*
08:25-08:35	Update on CRISP Study. Auke Beishuizen (PMC, NL)
08:35-08:50	New trial development with COG: current status (Charlotte Rigaud, Gustave Roussy,FR)*
08:50-9:00	Allogeneic SCT for consolidation of pediatric and adult relapsed ALK-pos ALCL: The French experience. David Sibon (Henri Mondor University Hospital, FR)*
09:00-09:10	Allogeneic SCT for consolidation of relapsed ALK-pos ALCL: MUD or MSD? BFM-data. Fabian Knörr (UKE-BFM Group-GER)
09:10-09:20	QM for minimal disease monitoring in ALK-pos ALCL: common analysis. Christine Damm-Welk (UKE-BFM Group-GE) and Lara Mussolin (IRP Padova, AIEOP, IT)
09:20-09:30	ALK negative ALCL molecular analysis. E James (CRUK Cambridge, UK) and J Salmeron (IDIBAPS-SEHOP-Group, ESP)
<b>09:30-10:00 COFFEE BREAK</b>	
<b>Session 2: Liquid biopsy in NHL Chairs: Christine Damm-Welk and Lara Mussolin.</b> <b>10:00-11:00 Auditorium Esteve, CEK</b>	
10:00-10:10	Liquid biopsy for ALCL: AIEOP experience. Lara Mussolin (IRP Padova, AIEOP)
10:10-10:20	ctDNA in ALK-pos ALCL: SFCE experience. Samuel Abbou (Gustave Roussy, FR)*
10:20-10:30	ctDNA for genotyping or MRD of ALK-pos ALCL: BFM exp. Fabian Knörr (UKE-BFM-GER)
10:30-10:40	Circulating tumor DNA in B-NHL: first results. Fabian Knörr (UKE-BFM Group-GER)
10:40-10:50	Circulating DNA in B-NHL. SEHOP experience. Sara Mato
10:50-11:00	Common discussion on Liquid biopsy in NHL
<b>SPECIAL SESSION</b> <b>11:00-11:30 Auditorium Esteve, CEK</b> <b>Topic: Epigenetic contributions to diagnosis and prognosis of lymphoid tumors</b> <b>Dr. Iñaki Martin-Subero (IDIBAPS Group leader)</b>	
<b>JOINT SESSION: Pathologists – Physicians - Researchers</b> <b>11:30 – 12:00 Auditorium Esteve, CEK</b> <b>Topic: Challenges in ALK-negative ALCL diagnosis in children. Summary of reviewed cases</b> <b>Dr. O. Balagué (H. Clinic-SEHOP Group, ESP)</b>	
<b>12:00-14:00 LUNCH meeting → eicnhl disease specific committees: set up and get the ball rolling!</b> <b>12:30-14:00, Working room, CEK</b>	
14:00	Upcoming eicnhl meetings and farewell. Itziar Salaverria / Olga Balagué / Birgit Burkhardt